Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Hippo Signaling in Cancer Immunity The Hippo pathway has evo
2022-01-03

Hippo Signaling in Cancer Immunity The Hippo pathway has evolutionarily conserved roles in limiting the size of organs [1]. It is a kinase cascade regulating transcriptional complexes in response to various upstream signals (Box 1). At the cellular level, the Hippo pathway inhibits cell proliferati
-
br Introduction Glycolysis plays a key
2022-01-03

Introduction Glycolysis plays a key role in SM-164 energy metabolism [[1], [2], [3]]. It is initiated mainly by hexokinase I (HKI), the major hexokinase isoform of the brain ([3,4] and references therein). Up to 90% of brain HKI is bound to the mitochondrial outer membrane (MOM) through the volt
-
According to the literature HER mutations are present in
2022-01-03

According to the literature, HER2 mutations are present in 2–4% of lung adenocarcinoma (ADC) patients. Most HER2 mutations are in-frame insertional mutations occurring at exon 20 in the protein kinase domain [[2], [3], [4], [5]]. Although several small molecules and HER2 2-Deoxyadenosine 5-diphospha
8493 records 567/567 page Previous First page 上5页 566567